Innate immune-checkpoint blockade with anti-CD47 antibodies have also shown activity in combination with rituximab by enhancing phagocytosis of malignant tumour cells in heavily pretreated DLBCL patients [194]. The gene discussed is CD47; the disease is neoplasm.